Why Canopy Growth (TSX:WEED) Stock Fell 12% This Week

Does the recent pullback in Canopy Growth Corporation (TSX:WEED)(NYSE:CGC) stock provide an opportunity for investors?

| More on:
Young adult woman walking up the stairs with sun sport background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The last week has not been good for cannabis investors. Leading cannabis stocks such as Canopy Growth (TSX:WEED)(NYSE:CGC) and Aurora Cannabis lost significant market value last week.

While Canopy Growth was down 12%, Aurora Cannabis fell close to 6% in the week ended August 16.

Canopy Growth announced its fiscal first quarter of 2020 (ended in June) results after market close on Wednesday. The company reported sales of $90.5 million in the first quarter, a fall of 4% sequentially.

reported earnings of -$0.30 per share. Analysts estimated sales of $86 million and earnings of -$0.37. So, why did Canopy shares fall despite beating earnings and sales estimates?

Investors were spooked with Canopy’s unadjusted net loss of $1.28 billion. These losses were attributed to Canopy’s expansion efforts and its recent acquisition deal with Acreage Holdings.

Canopy’s tepid sales in its cannabis oils and gels segment also left investors unimpressed, driving the stock lower by 14.5% on Thursday.

Canopy results impacted peer companies as well. Tilray fell 10% on Thursday, while Aurora Cannabis, CannTrust, and HEXO fell 6.9%, 6.6%, and 6.8% respectively on August 15.

What next for Canopy Growth?

Canopy Growth is focusing on leveraging its expertise to gain traction in an expanding global cannabis market. It will look to develop intellectual property, brand value, and a robust supply chain as it targets new markets.

In the first quarter, Canopy filed 56 patent applications across various products. It has 100 patents and 270 patent applications.

The company is also looking to transition from a builder to an operator. This essentially means that Canopy Growth will look to scale efficiently as its domestic market expansion program comes to an end. It would now want to develop a sustainable and profitable business in domestic markets.

Canopy Growth is likely to benefit as it becomes easier to get retail store licenses going forward. This will help the company open several Cannabis stores across the country.

Currently, Ontario and Quebec provinces have one store for every 595,00 and 495,000 people respectively. Comparatively, California has one store for 10,000 people.

Why improving bottom line will excite investors?

Canopy Growth expects to achieve an annual revenue run rate of $1 billion by the end of 2020. Analysts expect sales to rise by 200.6% to $680.47 million in 2020 and by 87.3% to $1.27 billion in 2021.

Canopy’s earnings growth is too estimated to be robust. Analysts expect bottom-line to increase by 58% to -$1.08 in 2020 and by 67.6% to -$0.35 in 2021.

There will be a massive boost to Canopy’s profit margins. The company should be profitable in the next three to five years. Canopy has had to raise capital to support its rapid growth. It raised $256 million in a stock issue two years back.

In the last fiscal, Constellation Brands invested $5 million for a 38% stake in Canopy. Further, Canopy raised debt of $600 million in fiscal 2019.

Canopy has a cash balance of $3.14 billion and debt of $805.8 million. It has enough reserves to pay back debt, invest in capital expenditure and grow inorganically via partnerships and acquisitions.

Now, if Canopy can just focus on improving bottom-line successfully, the stock will rise at an exponential rate.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »